title: Allogeneic stem cell transplantation in patients with β-thalassemia: King Faisal specialist hospital and research centre experience.
abstract: From January 1998-July 2006, 62 stem cell transplantation (SCT) were performed on 60 patients with beta-thalassemia from HLA-related match donors. The overall survival (OS) and event free survival (EFS) for all patients were 94 and 77%. The outcome of allogeneic SCT in our experience is satisfactory with OS 92% and EFS 77%. Transplantation at a young age and when the disease is mild offers the best outcome. More advanced disease is associated with higher rate of rejection and severe graft versus host disease.
authors.affiliation: King Faisal Specialist Hospital and Research Centre (KFSH&RC), Riyadh, Saudi Arabia. ajefri@kfshrc.edu.sa
authors.forename: A
authors.initials: A
authors.lastname: Al-Jefri
authors.forename: A
authors.initials: A
authors.lastname: Ayas
authors.forename: A
authors.initials: A
authors.lastname: Al Musa
authors.forename: M
authors.initials: M
authors.lastname: Al Mahr
authors.forename: M
authors.initials: M
authors.lastname: Al Saleh
authors.forename: S
authors.initials: S
authors.lastname: Rifai
authors.forename: R
authors.initials: R
authors.lastname: Sabbah
authors.forename: A
authors.initials: A
authors.lastname: Al Seraihy
authors.forename: A
authors.initials: A
authors.lastname: Al Ahmari
authors.forename: E
authors.initials: E
authors.lastname: Khairy
authors.forename: I
authors.initials: I
authors.lastname: Al Hassan
authors.forename: H
authors.initials: H
authors.lastname: El Solh
mesh_terms: D006084:Graft Rejection / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006782:Hospitals, Special / Q000145:classification*; D006801:Humans; D012189:Retrospective Studies; D012307:Risk Factors; D012529:Saudi Arabia; D016019:Survival Analysis; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000150:complications / Q000401:mortality / Q000628:therapy*